Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …

Patients with severe aplastic anemia (SAA) are either treated with bone marrow transplant
(BMT) or immunosuppression (IST) depending on their age, comorbidities, and available …

Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …

Acquired aplastic anemia (AA) is characterized by a reduced stem cell reserve. Several
preclinical studies have confirmed the beneficial effect of thrombopoietin (TPO) on the …

About a quarter of patients with severe aplastic anemia remain pancytopenic despite
immunosuppressive therapy. We have previously demonstrated that eltrombopag has …

Background Severe aplastic anemia, which is characterized by immune-mediated bone
marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive …

Acquired severe aplastic anaemia (SAA) has an immune pathogenesis, and
immunosuppressive therapy (IST) with anti‐thymocyte globulin and cyclosporine is effective …

Since the approval of horse antithymocyte globulin (ATG) decades ago, there was a long
hiatus in therapies with activity in severe aplastic anemia (SAA). This scenario changed in …

Background Acquired aplastic anemia results from immune-mediated destruction of bone
marrow. Immunosuppressive therapies are effective, but reduced numbers of residual stem …

Eltrombopag (ELT), an oral thrombopoietin receptor agonist, has recently emerged as a
promising new drug for the treatment of aplastic anemia (AA). How ELT is used outside of …